Senti Biosciences Holdings (SNTI) Cash from Investing Activities (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Cash from Investing Activities of -$184000.0 for Q2 2025, down 1572.73% quarter-over-quarter from -$11000.0 in Q4 2024.
Senti Biosciences Holdings (SNTI) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$184000.0 for Q2 2025.
- In Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$184000.0; the TTM figure through Dec 2025 stood at -$184000.0 (down 641.18% YoY), while the FY2025 annual figure was -$184000.0, down 641.18% from the prior year.
- Cash from Investing Activities for Q2 2025 stood at -$184000.0, down from -$11000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $21.1 million in Q3 2023, with the low at -$230.0 million in Q2 2021.
- The 5-year median for Cash from Investing Activities is -$7.4 million (2022), against an average of -$49.5 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 262.8% in 2023, then sank 110.89% in 2024.
- Senti Biosciences Holdings' Cash from Investing Activities stood at -$230.0 million in 2021, then soared by 78.64% to -$49.1 million in 2022, then jumped by 100.21% to $101000.0 in 2023, then tumbled by 110.89% to -$11000.0 in 2024, then tumbled by 1572.73% to -$184000.0 in 2025.
- Business Quant data shows SNTI's Cash from Investing Activities at -$184000.0 in Q2 2025, -$11000.0 in Q4 2024, and $60000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -184,000.00 |
| Jun 30, 2025 | -184,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | 21.14 Mn |
| Sep 30, 2023 | 21.14 Mn |
| Jun 30, 2023 | 18.33 Mn |
| Jun 30, 2023 | 18.33 Mn |
| Mar 31, 2023 | -9.50 Mn |
| Mar 31, 2023 | -9.50 Mn |
| Dec 31, 2022 | -49.12 Mn |
| Dec 31, 2022 | -49.12 Mn |
| Sep 30, 2022 | -14.20 Mn |
| Sep 30, 2022 | -14.20 Mn |